Carl L Gordon bought $15.0M of Scribe Therapeutics (SCTX)
Executed Jul 27, disclosed Jul 29, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jul 29), the stock returned +75.6% (delay-adjusted); from the execution session (Jul 27), +73.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Carl L Gordon (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in BlossomHill Therapeutics, Inc. Common Stock (BLSM). Across 2 priced purchase filings, the average 21-session return was +56.2% from execution and +52.9% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of SCTX (1,000,000 sh × $15.00, as filed), executed Jul 27.
Healthcare · Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→